Radar On – September 2018: CVS Will Exclude Certain Drugs Based on ICER Analyses of QALY

“The question is how this will affect innovative drugs where there are fewer alternatives for patients. Any decision to use this approach needs to also be carefully evaluated in the context of how it could help or harm patients, which I’m sure CVS will do.…I can’t see a lot of benefits to this approach.”
–Lisa Kennedy